Hepatology

Papers
(The H4-Index of Hepatology is 70. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Reply: Fiber and whole grain intakes in relation to liver cancer risk—An analysis in 2 prospective cohorts and systematic review and meta-analysis of prospective studies3066
Reply: Liver stiffness progression comparison between diabetics and non-diabetics with biopsy-proven metabolic dysfunction–associated steatosis2586
Honey, I shrunk the tumor: Downstaging HCC before liver transplantation2334
Stellate cell-specific adhesion molecule protocadherin 7 regulates sinusoidal contraction1740
Letter to the Editor: Regarding terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury578
Reply: Medications promoting abstinence in alcohol-associated cirrhosis417
Late-Breaking Abstracts379
Post-vax vein vigilance: Unmasking splanchnic thrombosis risks335
Hepatic encephalopathy—We are no longer those who believe that reality is what we perceive283
Letter to the Editor: Real-world evidence supports nephrotoxic risk of anakinra plus zinc in alcohol-associated hepatitis267
Reply240
Reply: Can pFIB scores reliably exclude significant liver fibrosis in pediatric MASLD?215
Biopsy-free endpoints in MASH trials: A comparative look at MASHResInd and FAST206
Reply: Timing shapes adjuvant PD-1 efficacy after hepatectomy in HCC206
Retraction: GABA induces the differentiation of small into large cholangiocytes by activation of Ca2+/CaMK I-dependent adenylyl cyclase 8194
Implementation of a controlled human infection model for evaluation of HCV vaccine candidates168
Letter to the Editor: Insurance should cover vancomycin for primary sclerosing cholangitis167
Letter to the Editor: LO2, a misidentified cell line: Some data should be interpreted with caution165
Low-dose chemotherapy remodels hepatic immune landscape and potentiates antitumor response to immune checkpoint blockade in cholangiocarcinoma164
Precipitous changes in nomenclature and definitions—NAFLD becomes SLD: Implications for and expectations of AASLD journals162
Moving beyond the liver—Proteomics as a molecular footprint of systemic damage in metabolic dysfunction–associated steatotic liver disease149
Plasma proteomic signature of fatty liver disease: The Rotterdam Study143
Letter to the Editor: The Hepa 1–6 may not be suitable for use in hepatocellular carcinoma models to explore responses to drug therapy142
Letter to the Editor: Assessing HCC incidence and surveillance thresholds in non-cirrhotic MASLD133
More immunosuppressive, more immunotherapy responsive? A double-edged sword of HBV-induced immune response in HCC133
ZNT1 and Zn2+ control TLR4 and PD-L1 endocytosis in macrophages to improve chemotherapy efficacy against liver tumor131
Reply: The PNPLA3 paradox—Does genotype modify the clinical utility of the MASLD framework in children?130
Regulatory role and translational potential of CCL11 in liver fibrosis128
Validation and expansion of Baveno VII criteria for cACLD and CSPH based on liver stiffness and platelet count: Correlation with risk of hepatic decompensation and death126
Effectiveness and safety of glecaprevir/pibrentasvir for 8 weeks in the treatment of patients with acute hepatitis C: A single-arm retrospective study121
Boosting Success: Optimizing Thiopurine Therapy in Autoimmune Hepatitis With Allopurinol121
Letter to the editor: Targeted decrease of portal hepatic pressure gradient immediately after TIPS improves ascites control and prognosis116
Development and validation of risk stratification models for hepatocellular cancer: A framework from the translational liver cancer consortium114
Definition, diagnosis, and treatment of primary biliary cholangitis–autoimmune hepatitis (PBC–AIH) variant: An international expert Delphi consensus113
Efficacy and safety of infliximab in patients with autoimmune hepatitis109
Acute encephalopathy without hyperammonemia has a different presentation than overt HE and displays a similarly severe prognosis107
Multi-omics approaches for identifying the PANoptosis signature and prognostic model via a multimachine-learning computational framework for intrahepatic cholangiocarcinoma105
Comparison of pharmacological therapies in metabolic dysfunction–associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis104
PGD2/DP1 axis promotes liver regeneration by secreting Wnt2 in KCs in mice103
Higher level of HBsAg associated with delayed development of HCC in immune-tolerant patients100
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease99
96
Letter to the Editor: Primary sclerosing cholangitis and autoimmune hepatitis—Distinct or common autoimmune penetrance?94
Genes that fit just right: Unzipping the genome of fatty liver disease94
Letter to the Editor: Learning more about the safety of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma94
Erratum: AASLD Practice Guidance on Acute-on-chronic liver failure and the management of critically ill patients with cirrhosis93
In vivo imaging of calcium dynamics in zebrafish hepatocytes93
Reply: The CRAPT-M score: Robust enough for clinical practice?92
Letter to the Editor: Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat content—Systematic review and network meta-analysis91
Deciphering the spatial tumor microenvironment in intrahepatic cholangiocarcinoma91
Understanding advanced cystic fibrosis liver disease through genetic variation: Where do the pathways lead and how much further must we go?87
Letter to the Editor: Enhancing the rigor and impact of cholangiocarcinoma research: Addressing key concerns in the PTPN9-FGFR2 interaction study87
Use of noninvasive scores to predict hepatic steatosis: Flaws and caveats87
Erratum: Identification and characterization of a hepatic IL-13–producing ILC3-like population potentially involved in liver fibrosis86
Reply: How does bile acid–induced IRF3 phosphorylation mediate cholestatic liver and kidney injury?—More needs to be known84
Letter to the Editor: Overlooking the important factor: Hypoxia84
Computational drug prediction in hepatoblastoma by integrating pan-cancer transcriptomics with pharmacological response83
The international quest for the imaging diagnosis of liver cancer82
Much more needed in natural history of Alagille syndrome81
Letter to the Editor: Screening and risk stratification disparities in Hispanic MASLD78
CD4+ T cells promote fibrosis during metabolic dysfunction–associated steatohepatitis76
5S rRNA pseudogene transcripts are associated with interferon production and inflammatory responses in alcohol-associated hepatitis76
Erratum: Vps4A functions as a tumor suppressor by regulating the secretion and uptake of exosomal microRNAs in human hepatoma cells76
Erratum: Effects of trientine and penicillamine on intestinal copper uptake: A mechanistic 64Cu PET/CT study in healthy humans75
Letter to the Editor: Insights into immune-mediated adverse events and survival outcomes—Lessons from HIMALAYA75
Divergent trends in cirrhosis and liver cancer highlight the ongoing efforts required for hepatitis elimination75
Letter to the Editor: Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatm75
Stard1 promotes cholestatic liver injury and disease progression by sensitizing to bile acid hepatotoxicity74
Hepatocellular carcinoma with macrovascular invasion: Navigating heterogeneous evidence72
Reply: Diabetes and fibrosis—Parallel risks or overlap?70
0.09722900390625